Comparing of vTv Therapeutics Inc. (VTVT) and Prana Biotechnology Limited (NASDAQ:PRAN)

Both vTv Therapeutics Inc. (NASDAQ:VTVT) and Prana Biotechnology Limited (NASDAQ:PRAN) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
vTv Therapeutics Inc. 8.14M 14.00 11.13M -0.52 0.00
Prana Biotechnology Limited N/A 0.00 N/A -0.67 0.00

Demonstrates vTv Therapeutics Inc. and Prana Biotechnology Limited earnings per share, gross revenue and valuation.


Table 2 provides us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
vTv Therapeutics Inc. -136.73% 10.7% -68.5%
Prana Biotechnology Limited 0.00% -37.8% -34.3%

Volatility and Risk

vTv Therapeutics Inc. has a -3.82 beta, while its volatility is 482.00% which is more volatile than S&P 500. Prana Biotechnology Limited on the other hand, has -0.11 beta which makes it 111.00% less volatile compared to S&P 500.


vTv Therapeutics Inc. has a Current Ratio of 0.2 and a Quick Ratio of 0.2. Competitively, Prana Biotechnology Limited’s Current Ratio is 7.1 and has 7.1 Quick Ratio. Prana Biotechnology Limited’s better ability to pay short and long-term obligations than vTv Therapeutics Inc.

Institutional and Insider Ownership

The shares of both vTv Therapeutics Inc. and Prana Biotechnology Limited are owned by institutional investors at 3.6% and 3.5% respectively. vTv Therapeutics Inc.’s share held by insiders are 0.5%. On the other hand, insiders held about 18.7% of Prana Biotechnology Limited’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
vTv Therapeutics Inc. 8.88% -30.57% 97.85% 1.66% -60.34% -69.38%
Prana Biotechnology Limited -9.31% -14.69% -22.56% -22.61% -50.97% -51.6%

For the past year vTv Therapeutics Inc. was more bearish than Prana Biotechnology Limited.


Prana Biotechnology Limited beats vTv Therapeutics Inc. on 5 of the 9 factors.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. Its type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. operates as a subsidiary of M&F TTP Holdings Two LLC.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.